TD-6450

TD-6450 is a next-generation, orally administered small molecule inhibitor targeting the hepatitis C virus (HCV) NS5A protein. It was discovered and initially developed by Theravance Biopharma. TD-6450 is a multivalent NS5A inhibitor designed to have improved antiviral activity against genotype 1 resistance-associated variants (RAVs) that are resistant to first-generation NS5A inhibitors. Its heterodimeric structure allows for an asymmetric binding mode to the NS5A protein, distinguishing it from structurally symmetric inhibitors. In clinical studies, TD-6450 demonstrated dose-dependent antiviral activity and was generally well-tolerated in healthy subjects and HCV-infected patients. The drug has been evaluated in combination with other antivirals such as faldaprevir (a protease inhibitor) and ribavirin for the treatment of hepatitis C infection, including genotype 4 HCV[1][3][4][5]. There is also evidence suggesting potential anti-malarial effects in vitro[6].